Chimerix INC

Chimerix, Inc. has been acquired by Jazz Pharmaceuticals following the completion of a tender offer and subsequent merger on April 21, 2025.

Chimerix announces its Q4 and full-year 2024 financial results, highlighting the FDA acceptance of the dordaviprone NDA and the pending acquisition by Jazz Pharmaceuticals expected to close in the second quarter of 2025.

Chimerix, Inc. is being acquired by Jazz Pharmaceuticals Public Limited Company for $8.55 per share, aiming to enhance Jazz's oncology portfolio with Chimerix's dordaviprone.

Jazz Pharmaceuticals will acquire Chimerix for $8.55 per share in cash, a deal valued at approximately $935 million, to expand its oncology portfolio with dordaviprone, a treatment for rare brain tumors.

Chimerix, Inc. will pause enrollment in the U.S. portion of its Phase 3 ACTION study for dordaviprone due to the ongoing FDA review of its New Drug Application (NDA).

Chimerix, Inc. has entered into a $30 million loan agreement, regained compliance with Nasdaq listing rules, and submitted a new drug application to the FDA.

Chimerix, Inc. released its third quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Chimerix, Inc. released its second quarter 2024 financial results and provided an update on its clinical development programs, including the ongoing Phase 3 ACTION trial for dordaviprone.

Chimerix reports a net loss of $21.9 million for the first quarter of 2024, while its Phase 3 ACTION study for dordaviprone continues to enroll patients.

Chimerix files an amendment to its 2024 annual report to include Part III information due to the pending acquisition by Jazz Pharmaceuticals for $935 million.

Chimerix has entered into a merger agreement with Jazz Pharmaceuticals for approximately $935 million and filed its 10-K report detailing its financial results for the year ended December 31, 2024, along with updates on its drug development programs.

Chimerix, a biopharmaceutical company, released its 2023 financial results and provided updates on its clinical development programs, including the ongoing Phase 3 ACTION study for ONC201.

Director Victoria Vakiener reports the disposal of Chimerix stock options following the company's merger with Jazz Pharmaceuticals on April 21, 2025.

Following the merger of Chimerix with Jazz Pharmaceuticals, CEO Michael Sherman reports the disposal of common stock and cancellation of stock options.

Thomas Riga, COO and CCO of Chimerix, reports the disposal of common stock and stock options following the merger with Jazz Pharmaceuticals, as per the terms of the merger agreement.

Director Pratik S. Multani reports the disposal of employee stock options in Chimerix following the company's merger with Jazz Pharmaceuticals, where Chimerix became a wholly-owned subsidiary.

Director Fred A. Middleton reports the disposal of Chimerix shares and options due to the merger with Jazz Pharmaceuticals, where shares were acquired for $8.55 each.

Robert J. Meyer, a director of Chimerix, reported the disposal of common stock and stock options due to the merger with Jazz Pharmaceuticals, where Chimerix became a wholly-owned subsidiary.

Chimerix, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.

Chimerix is asking stockholders to approve the 2024 Equity Incentive Plan to replace the 2013 plan and attract key talent.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, indicating they no longer hold beneficial ownership in Chimerix, Inc.